Marie Nour Karam, Sandra K Althouse, Madeline G Andrews, Jenny Chen, Sandeep Batra
{"title":"Characteristics and Outcomes of Acute Leukemias in Adolescents and Young Adults with Down Syndrome: A Single-Center Experience.","authors":"Marie Nour Karam, Sandra K Althouse, Madeline G Andrews, Jenny Chen, Sandeep Batra","doi":"10.3390/hematolrep17060070","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives:</b> Acute leukemias in adolescents and young adults (AYAs) with Down Syndrome (DS) are understudied. <b>Methods</b>: This was a single-center, retrospective cohort study. Medical records for pediatric DS (<i>n</i> = 41) and AYA-DS (<i>n</i> = 7) treated with a pediatric chemotherapy regimen for acute leukemia were evaluated. <b>Results</b>: Two-year event-free survival (EFS) in AYA DS acute leukemia patients was lower than that in their pediatric DS counterparts (28.6% (Confidence Interval (CI) 4.1, 61.2) vs. 84.9% (CI 69.5, 92.9); <i>p</i> = 0.002). <b>Conclusions</b>: Additional research is needed to improve outcomes in AYA DS leukemia.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"17 6","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12733178/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/hematolrep17060070","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background/Objectives: Acute leukemias in adolescents and young adults (AYAs) with Down Syndrome (DS) are understudied. Methods: This was a single-center, retrospective cohort study. Medical records for pediatric DS (n = 41) and AYA-DS (n = 7) treated with a pediatric chemotherapy regimen for acute leukemia were evaluated. Results: Two-year event-free survival (EFS) in AYA DS acute leukemia patients was lower than that in their pediatric DS counterparts (28.6% (Confidence Interval (CI) 4.1, 61.2) vs. 84.9% (CI 69.5, 92.9); p = 0.002). Conclusions: Additional research is needed to improve outcomes in AYA DS leukemia.